Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/38660
Title: | PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges. | Authors: | Rashid H.;Meredith I.T. ;Nasis A. | Institution: | (Rashid, Meredith, Nasis) Monash Cardiovascular Research Centre, MonashHEART, Monash Health and Monash University Department of Medicine (MMC), Melbourne, Vic, Australia | Issue Date: | 7-Jul-2017 | Copyright year: | 2017 | Publisher: | Elsevier Ltd | Place of publication: | United Kingdom | Publication information: | Heart Lung and Circulation. 26 (8) (pp 786-798), 2017. Date of Publication: August 2017. | Journal: | Heart Lung and Circulation | Abstract: | Cardiovascular disease remains the leading cause of morbidity and mortality in developed nations, with elevated low-density lipoprotein-cholesterol (LDL-C) levels being a major modifiable risk factor for coronary atherosclerosis. While lipid-lowering therapies such as statins are effective in lowering LDL-C, a proportion of patients do not achieve target LDL-C goals with statins or are intolerant to statins necessitating other treatment options. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of agents that reduce LDL-C beyond the maximum achievable LDL-C reductions with statins, and have been well studied in different patient groups. However, there are concerns regarding their potential adverse effects and cost, given that morbidity and mortality benefits have not yet been demonstrated. This state-of-the art review provides an overview of the development of PCSK9 inhibitors, the evidence regarding their clinical efficacy in specific target populations, and highlights future trials and challenges that need to be addressed before PCSK9 inhibitors are widely adopted into contemporary clinical practice.Copyright © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ) | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.hlc.2016.12.005 | Link to associated publication: | Click here for full text options | PubMed URL: | 28286091 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28286091] | ISSN: | 1443-9506 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/38660 | Type: | Review | Subjects: | cognitive defect/si [Side Effect] confusion/si [Side Effect] congestive heart failure/si [Side Effect] coronary artery atherosclerosis/dt [Drug Therapy] demyelination/si [Side Effect] disorders of higher cerebral function/si [Side Effect] drug cost drug research familial hypercholesterolemia/dm [Disease Management] familial hypercholesterolemia/dt [Drug Therapy] fatigue/si [Side Effect] headache/si [Side Effect] heart infarction/si [Side Effect] heart muscle revascularization human hypercholesterolemia/dt [Drug Therapy] hyperlipidemia/dt [Drug Therapy] injection site reaction/si [Side Effect] ischemic heart disease/si [Side Effect] memory disorder/si [Side Effect] meta analysis (topic) monotherapy multicenter study (topic) myalgia/si [Side Effect] neuritis/si [Side Effect] nonhuman phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal protein function randomized controlled trial (topic) review alirocumab/sc [Subcutaneous Drug Administration] aspartate aminotransferase/ec [Endogenous Compound] bococizumab/ct [Clinical Trial] bococizumab/cm [Drug Comparison] bococizumab/dt [Drug Therapy] creatinine/ec [Endogenous Compound] evolocumab/ae [Adverse Drug Reaction] evolocumab/ct [Clinical Trial] evolocumab/cm [Drug Comparison] evolocumab/dt [Drug Therapy] ezetimibe/ct [Clinical Trial] ezetimibe/cm [Drug Comparison] ezetimibe/dt [Drug Therapy] hydroxymethylglutaryl coenzyme A reductase inhibitor/ae [Adverse Drug Reaction] hydroxymethylglutaryl coenzyme A reductase inhibitor/dt [Drug Therapy] *monoclonal antibody/ct [Clinical Trial] *monoclonal antibody/dt [Drug Therapy] placebo *proprotein convertase 9/ec [Endogenous Compound] unclassified drug *monoclonal antibody proprotein convertase 9/ct [Clinical Trial] *monoclonal antibody proprotein convertase 9/dt [Drug Therapy] phase 1 clinical trial (topic) side effect/si [Side Effect] unstable angina pectoris/si [Side Effect] alanine aminotransferase/ec [Endogenous Compound] alirocumab/ae [Adverse Drug Reaction] alirocumab/ct [Clinical Trial] alirocumab/cm [Drug Comparison] alirocumab/dt [Drug Therapy] alirocumab/pe [Pharmacoeconomics] amnesia/si [Side Effect] arthralgia/si [Side Effect] ataxia/si [Side Effect] brain ischemia/si [Side Effect] cardiovascular disease/si [Side Effect] clinical effectiveness clinical practice drug cost drug research familial hypercholesterolemia / disease management / drug therapy fatigue / side effect headache / side effect heart infarction / side effect heart muscle revascularization human hypercholesterolemia / drug therapy hyperlipidemia / drug therapy injection site reaction / side effect ischemic heart disease / side effect memory disorder / side effect meta analysis (topic) monotherapy multicenter study (topic) myalgia / side effect neuritis / side effect nonhuman phase 1 clinical trial (topic) phase 2 clinical trial (topic) phase 3 clinical trial (topic) priority journal protein function cardiovascular disease / side effect Review side effect / side effect unstable angina pectoris / side effect brain ischemia / side effect ataxia / side effect arthralgia / side effect amnesia / side effect randomized controlled trial (topic) clinical effectiveness clinical practice cognitive defect / side effect confusion / side effect congestive heart failure / side effect coronary artery atherosclerosis / drug therapy demyelination / side effect disorders of higher cerebral function / side effect |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.